BDTX
Price
$2.70
Change
+$0.01 (+0.37%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
152.69M
104 days until earnings call
Intraday BUY SELL Signals
XOMA
Price
$31.10
Change
+$0.10 (+0.32%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
383.88M
91 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BDTX vs XOMA

Header iconBDTX vs XOMA Comparison
Open Charts BDTX vs XOMABanner chart's image
Black Diamond Therapeutics
Price$2.70
Change+$0.01 (+0.37%)
Volume$25.46K
Capitalization152.69M
XOMA Royalty
Price$31.10
Change+$0.10 (+0.32%)
Volume$900
Capitalization383.88M
BDTX vs XOMA Comparison Chart in %
BDTX
Daily Signal:
Gain/Loss:
XOMA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BDTX vs. XOMA commentary
Dec 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDTX is a Hold and XOMA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 05, 2025
Stock price -- (BDTX: $2.69 vs. XOMA: $31.00)
Brand notoriety: BDTX and XOMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BDTX: 826% vs. XOMA: 182%
Market capitalization -- BDTX: $152.69M vs. XOMA: $383.88M
BDTX [@Biotechnology] is valued at $152.69M. XOMA’s [@Biotechnology] market capitalization is $383.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BDTX’s FA Score shows that 0 FA rating(s) are green whileXOMA’s FA Score has 1 green FA rating(s).

  • BDTX’s FA Score: 0 green, 5 red.
  • XOMA’s FA Score: 1 green, 4 red.
According to our system of comparison, both BDTX and XOMA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BDTX’s TA Score shows that 4 TA indicator(s) are bullish while XOMA’s TA Score has 4 bullish TA indicator(s).

  • BDTX’s TA Score: 4 bullish, 5 bearish.
  • XOMA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, XOMA is a better buy in the short-term than BDTX.

Price Growth

BDTX (@Biotechnology) experienced а -28.84% price change this week, while XOMA (@Biotechnology) price change was -4.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.21%. For the same industry, the average monthly price growth was +5.86%, and the average quarterly price growth was +56.03%.

Reported Earning Dates

BDTX is expected to report earnings on Mar 18, 2026.

XOMA is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+1.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XOMA($384M) has a higher market cap than BDTX($153M). XOMA has higher P/E ratio than BDTX: XOMA (41.33) vs BDTX (7.27). BDTX YTD gains are higher at: 25.701 vs. XOMA (17.960). BDTX has higher annual earnings (EBITDA): 5.05M vs. XOMA (-305K). BDTX has more cash in the bank: 143M vs. XOMA (83.9M). BDTX has less debt than XOMA: BDTX (20.8M) vs XOMA (115M). BDTX has higher revenues than XOMA: BDTX (70M) vs XOMA (12.8M).
BDTXXOMABDTX / XOMA
Capitalization153M384M40%
EBITDA5.05M-305K-1,655%
Gain YTD25.70117.960143%
P/E Ratio7.2741.3318%
Revenue70M12.8M547%
Total Cash143M83.9M170%
Total Debt20.8M115M18%
FUNDAMENTALS RATINGS
BDTX vs XOMA: Fundamental Ratings
BDTX
XOMA
OUTLOOK RATING
1..100
5974
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
2
Undervalued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
6294
PRICE GROWTH RATING
1..100
4059
P/E GROWTH RATING
1..100
9948
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XOMA's Valuation (2) in the Biotechnology industry is somewhat better than the same rating for BDTX (49) in the null industry. This means that XOMA’s stock grew somewhat faster than BDTX’s over the last 12 months.

XOMA's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as BDTX (100) in the null industry. This means that XOMA’s stock grew similarly to BDTX’s over the last 12 months.

BDTX's SMR Rating (62) in the null industry is in the same range as XOMA (94) in the Biotechnology industry. This means that BDTX’s stock grew similarly to XOMA’s over the last 12 months.

BDTX's Price Growth Rating (40) in the null industry is in the same range as XOMA (59) in the Biotechnology industry. This means that BDTX’s stock grew similarly to XOMA’s over the last 12 months.

XOMA's P/E Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for BDTX (99) in the null industry. This means that XOMA’s stock grew somewhat faster than BDTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BDTXXOMA
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 14 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
BDTX
Daily Signal:
Gain/Loss:
XOMA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IFUS0.04N/A
+7.53%
Impact Fusion International Inc.
ANOIX23.630.32
+1.37%
American Century Small Cap Growth Inv
DRTCX21.840.03
+0.14%
BNY Mellon Sust US Equity I
EKJAX12.66N/A
N/A
Allspring Premier Large Co Gr A
PMHG54.31N/A
N/A
Prime Meridian Holding Co.

BDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BDTX has been loosely correlated with RLAY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BDTX jumps, then RLAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BDTX
1D Price
Change %
BDTX100%
-22.03%
RLAY - BDTX
50%
Loosely correlated
+4.54%
RXRX - BDTX
43%
Loosely correlated
+7.87%
BEAM - BDTX
43%
Loosely correlated
+14.42%
CRBU - BDTX
43%
Loosely correlated
+5.68%
DNLI - BDTX
43%
Loosely correlated
+6.50%
More

XOMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, XOMA has been loosely correlated with SYRE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if XOMA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMA
1D Price
Change %
XOMA100%
+4.17%
SYRE - XOMA
42%
Loosely correlated
+13.38%
FHTX - XOMA
41%
Loosely correlated
+3.50%
BDTX - XOMA
40%
Loosely correlated
-22.03%
FENC - XOMA
38%
Loosely correlated
-0.53%
ZNTL - XOMA
38%
Loosely correlated
+2.99%
More